These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21128592)

  • 1. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
    Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
    J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Goodwin NC; Mabon R; Harrison BA; Shadoan MK; Almstead ZY; Xie Y; Healy J; Buhring LM; DaCosta CM; Bardenhagen J; Mseeh F; Liu Q; Nouraldeen A; Wilson AG; Kimball SD; Powell DR; Rawlins DB
    J Med Chem; 2009 Oct; 52(20):6201-4. PubMed ID: 19785435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Wu SH; Huang CY; Huang YL; Wang MH; Liu YW; Tsai CH; Kumar CR; Lee JC
    Eur J Med Chem; 2012 Sep; 55():32-8. PubMed ID: 22818040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
    Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
    Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 11. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment.
    Kakinuma H; Oi T; Hashimoto-Tsuchiya Y; Arai M; Kawakita Y; Fukasawa Y; Iida I; Hagima N; Takeuchi H; Chino Y; Asami J; Okumura-Kitajima L; Io F; Yamamoto D; Miyata N; Takahashi T; Uchida S; Yamamoto K
    J Med Chem; 2010 Apr; 53(8):3247-61. PubMed ID: 20302302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
    Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
    Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Ohtake Y; Sato T; Matsuoka H; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Higuchi T; Murakata M; Kobayashi T; Morikawa K; Shimma N; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
    Bioorg Med Chem; 2011 Sep; 19(18):5334-41. PubMed ID: 21873071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
    Pan X; Huan Y; Shen Z; Liu Z
    Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
    Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.